SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · T. Rowe Price stake 11.6%

Vaxcyte, Inc. · SC 13G/A filed Nov 6, 2026 at 11:07 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 6, 2026 at 11:07 ET

T. Rowe Price Investment Management filed an amended Schedule 13G disclosing an 11.6% passive stake in Vaxcyte as of October 31, 2026, up from 9.6% in the prior filing. The increase reflects continued accumulation by a major institutional holder following positive Phase 3 data for VAX-31 and a recent $1.1B capital raise.

  • T. Rowe Price Investment Management disclosed beneficial ownership of 18,136,166 shares of Vaxcyte common stock as of October 31, 2026.
  • The stake represents 11.6% of shares outstanding, up from 9.6% in the prior filing.
  • The filing is a passive investor update under Rule 13d-1(b); the investor certifies shares were not acquired to influence control.
  • T. Rowe Price Capital Appreciation Fund holds 7,430,887 shares (5.2% of class) within the total.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access